Akums Drugs and Pharmaceuticals valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025
Price multiples — at each FY-end close
35.08×——
3.09×——
2.27×——
10.77×——
Enterprise multiples
2.21×——
17.51×——
24.30×——
Yield
2.9%——
9.3%——
Reference — adjusted share basis
₹668.50——
₹19.05₹16.67₹22.09
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AKUMS₹668.50

Akums Drugs and Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersALIVUSAGARWALEYEADVENZYMESAPLLTDAARTIPHARMAARTIDRUGSCORONAHCGMcap ₹10,235 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E——35.08
P/B——3.09
P/Sales——2.27
Price to Free Cash Flow——10.77
Enterprise Multiples
EV/Sales——2.21
EV/EBITDA——17.51
EV/EBIT——24.30
Yield
Earnings Yield %——2.85
FCF Yield %——9.29
Reference — adjusted share basis
Price (FY-end close, adj.)——668.50
EPS (adj.)22.0916.6719.05
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.